Abbott
Global healthcare company manufacturing medical devices
Mechanical Engineer 2
International travel required, approximately 10% of the time.
About the job
- A Bachelor's Degree in Mechanical Engineering, or an equivalent combination of education and work experience.
- At least 3 years of experience.
- Experience with SolidWorks or other computer-aided design (CAD) tools.
- Ability to work within a team and as an individual contributor in a fast-paced, changing environment.
- Ability to leverage and/or engage others to accomplish projects.
- Strong verbal and written communication skills with the ability to communicate effectively at multiple organizational levels.
- Ability to multitask, prioritize, and meet deadlines in a timely manner.
- Strong organizational and follow-up skills and attention to detail.
- Ability to work in a highly matrixed and geographically diverse business environment.
- Ability to travel, including internationally.
- Compliance with U.S. Food and Drug Administration regulations, other regulatory requirements, company policies, operating procedures, processes, and task assignments.
- Design sub-assemblies to meet broad design goals and establish requirements and specifications.
- Use empirical, numerical, and experimental analysis to analyze designs.
- Participate in test-method and model development.
- Identify and mitigate sub-assembly risks.
- Support invention disclosures.
- Work with internal departments and external vendors to obtain prototype parts and understand their capabilities and limitations.
- Support pre-clinical and clinical testing of devices.
- Support design reviews and physician visits.
- Develop a detailed understanding of the clinical environment, including current treatment methods and evolving clinical needs.
- Develop a detailed understanding of the quality and regulatory requirements of SJM, the U.S. Food and Drug Administration, and ISO regulations, and manage projects within those requirements.
- Develop a detailed understanding of the overall schedule and manage time and tasks within the schedule.
- Support company initiatives and quality management systems, environmental management systems, and other regulatory requirements.
- Maintain positive and cooperative communication and collaboration with employees, customers, contractors, and vendors.
- Experience designing and testing relevant medical devices.
- Experience with a wide variety of manufacturing processes and design for manufacturability (DFM).
- Experience with analytical design, design for Six Sigma, or a similar toolset.
- Experience working in a broader enterprise or cross-division business-unit model.
About the company
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
Get referred to Abbott
See people who can refer or advise you
Simplify's Take
What believers are saying
- Abbott raised Q2 2026 adjusted EPS guidance to $5.45-$5.60 after $12.6 billion sales.
- TactiFlex Duo adds a fifth electrophysiology approval in just over a year.
- Uganda’s 500-machine mPIMA expansion deepens Abbott’s recurring diagnostics footprint across Africa.
What critics are saying
- Abbott paid $670 million in August 2026; 1,700 NEC lawsuits and 847 MDL cases remain.
- The $384 million DOJ formula settlement confirms contamination allegations still threaten Similac trust.
- Gill’s $495 million verdict and ongoing appeals keep existential infant-nutrition liability alive.
What makes Abbott unique
- Sept. 8, 2026 FDA approved TactiFlex Duo, combining pulsed field and radiofrequency ablation.
- Aug. 31, 2026 Similac launched whole-milk ready-to-feed formula, priced near powder.
- Sept. 2026 Uganda rollout shows Abbott’s diagnostics reach through mPIMA deployment and local support.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 14%Abbott faces $384 million cost as infant formula legal risks persist. Abbott will pay $384 million to resolve U.S. allegations over contaminated infant formula, easing one legal overhang while broader litigation risks remain. Published September 15, 2026 at 10:40 am EDT Abbott Laboratories (NYSE:ABT) has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in potentially contaminated environments at its Michigan and Arizona facilities, including allegations of inadequate testing and failure to disclose positive contamination tests to regulators. The settlement resolves civil claims without an admission of wrongdoing or a finding of liability, while the related criminal investigation has been closed. The case stems from Abbott's 2022 Similac recall, which followed contamination concerns at its Sturgis, Michigan plant and contributed to a nationwide infant-formula shortage. Abbott maintains that no unopened, distributed formula tested positive for contamination. Financially, the $384 million payment is significant but manageable relative to Abbott's scale. Abbott generated $12.6 billion of sales in Q2 2026 and raised its full-year adjusted EPS outlook to $5.45-$5.60, while returning $2.1 billion to shareholders during the quarter. The more important issue is therefore not the one-time cash settlement itself, but whether the resolution removes a major overhang around Abbott's Nutrition business and limits further regulatory or litigation costs. Formula settlement may let Abbott refocus on broader growth. The strongest bullish argument is that the settlement could mark an important step toward containing the financial and regulatory fallout from the 2022 formula crisis. The Justice Department says the agreement resolves the civil claims and that the related criminal investigation has been closed, reducing the probability of another major escalation from this particular matter. For investors, that provides greater visibility around the potential cash costs associated with the episode and allows Abbott Laboratories to focus on its broader portfolio rather than continuing to absorb uncertainty around the Sturgis-related controversy. The settlement also appears manageable against Abbott's earnings and cash-generation capacity. With 2026 adjusted EPS guidance of $5.45-$5.60 and Q2 sales of $12.6 billion, a $384 million settlement represents a material but not balance-sheet-threatening charge for a company of Abbott's size. More importantly, Abbott recently resolved a separate portion of litigation involving specialty formulas for preterm infants for approximately $670 million, covering the Gill case and claims involving roughly 2,000 individuals. If these settlements substantially reduce the remaining litigation uncertainty surrounding infant nutrition, the market could increasingly treat the issue as a contained legacy liability rather than a recurring threat to Abbott's valuation. There is also evidence that Abbott Laboratories's broader business remains capable of absorbing setbacks in Nutrition. The company reported 13% sales growth and 4.8% comparable sales growth in Q2, while maintaining its 6.5%-7.5% full-year comparable-sales growth forecast. That diversification matters because it reduces the likelihood that problems surrounding infant formula alone materially derail consolidated growth. The settlement could therefore be viewed as a cost of closing out a legacy problem while Abbott's larger medical-device, diagnostics and pharmaceutical businesses continue supporting earnings growth. Formula litigation could keep weighing on Abbott's risk profile. The principal bearish concern is that the $384 million payment reinforces the seriousness of the underlying manufacturing and regulatory allegations. The Justice Department alleged not simply an isolated contamination event, but deficiencies involving product testing and the disclosure of positive contamination tests to regulators. Even without an admission of wrongdoing, such allegations can damage trust in a category where safety and reliability are especially important. Abbott's infant-nutrition franchise depends heavily on consumer, hospital, and regulatory confidence, so reputational damage could have consequences beyond the immediate settlement. The 2022 episode has also already demonstrated that manufacturing disruption in Abbott Laboratories's formula business can have consequences far beyond a single product recall. The Sturgis plant closure contributed to a nationwide infant-formula shortage, and Abbott has subsequently faced continuing litigation related to its specialty formulas. Abbott's June 2026 10-Q said numerous NEC-related lawsuits remained outstanding and disclosed that a $495 million Missouri jury award had been affirmed on appeal, although Abbott was seeking further review. The existence of this broader litigation backdrop means investors cannot necessarily treat the $384 million settlement as the final cost of Abbott's infant-formula controversies. There is also a potential margin and cash-flow consideration if Abbott Laboratories must continue increasing quality-control, testing and compliance spending. Abbott has previously described enhanced pre- and post-production testing when restarting Similac production at Sturgis. Additional safeguards may be necessary to rebuild confidence, but they can raise manufacturing costs and reduce the economic benefit of the Nutrition business. If future recalls, settlements or legal judgments emerge, the cumulative cash burden could become more material than the latest $384 million payment suggests. Conclusion. Abbott Laboratories's $384 million settlement is financially manageable and reduces uncertainty by closing the DOJ case, but broader infant-formula litigation remains a risk. Overall, the news is modestly positive if it marks meaningful legal closure, but it does not eliminate Abbott's remaining regulatory, reputational, and litigation exposure.
Abbott's $670 million NEC settlement: what it means for Illinois families with pending or new claims. By Varun / Sep 10, 2026 Abbott Laboratories has agreed to pay $670 million to resolve lawsuits alleging its cow's-milk-based infant formulas, including Similac products designed for premature babies, increased the risk of a life-threatening bowel disease called necrotizing enterocolitis (NEC). The August 2026 settlement resolves claims involving roughly 2,000 infants, but for Illinois families, it is important to understand what this settlement does, and does not, mean for a new or pending claim. What the settlement covers, and what it doesn't. The $670 million settlement is a compromise of disputed claims, and Abbott has not admitted liability or wrongdoing as part of the deal. Just as importantly, this settlement does not end the litigation. According to court filings and public reporting, roughly 1,700 lawsuits covering claims on behalf of an additional 12,700 infants remain active, and more than 800 cases are still pending in the coordinated federal litigation, In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation (MDL No. 3026), before U.S. District Judge Rebecca R. Pallmeyer in the Northern District of Illinois, according to the official U.S. Judicial Panel on Multidistrict Litigation case report. In other words: if your family has not yet filed a claim, the door has not closed. This settlement resolved one large group of cases; it did not resolve the underlying litigation. (Note: this NEC litigation is separate from a different, largely-resolved case involving Abbott's 2022 Similac formula recall over bacterial contamination, the two involve different allegations and different infants.) What is necrotizing enterocolitis (NEC)? NEC is a serious, sometimes fatal intestinal disease that primarily affects premature infants, particularly those fed formula rather than human breast milk. It causes inflammation that can damage or destroy intestinal tissue, sometimes requiring emergency surgery, and it carries a real risk of death in severe cases. Families whose premature infants developed NEC after being fed Similac or Enfamil-brand cow's-milk-based formulas in the neonatal intensive care unit (NICU) may have grounds for a claim. The allegations against Abbott and Mead Johnson. The lawsuits allege that Abbott Laboratories (maker of Similac) and Mead Johnson (maker of Enfamil) knew, or should have known, that cow's-milk-based formula significantly increases the risk of NEC in premature infants compared to human milk or specialized formula, but failed to adequately warn parents and hospital staff about that risk. Earlier trials in this litigation produced substantial verdicts even before the recent settlement, including a $60 million jury verdict in the first trial to reach a verdict on these claims, and a $495 million verdict against Abbott in a separate case, which included a large punitive damages award. Those verdicts are being appealed and do not guarantee the outcome of any other case, but they reflect how juries have viewed the evidence presented so far. Why this case is in Chicago. The NEC formula litigation, like several other major product liability cases, has been consolidated before a single federal judge in the Northern District of Illinois for coordinated pretrial proceedings. That means the discovery disputes, expert testimony fights, and major rulings shaping this litigation are happening in Chicago's federal courthouse, even though the babies and families affected live all over the country, including right here in Illinois, where major NICUs at hospitals like Northwestern Memorial, Lurie Children's, Rush, and UChicago Medicine treat premature infants every day. Illinois families: what to do if your baby developed NEC. If your premature infant was fed Similac or Enfamil formula in the NICU and later developed NEC, whether your child recovered, required surgery, or did not survive, you may have an independent claim regardless of the recent Abbott settlement. Illinois recognizes both personal injury claims for surviving children and wrongful death claims for families who lost an infant to NEC. Frequently asked questions. Does the $670 million settlement mean the case is over? No. It resolves claims for about 2,000 infants specifically. More than 1,700 additional lawsuits, and hundreds of cases still pending in the federal court in Chicago, remain unresolved. My baby was fed both breast milk and formula. Can I still file a claim? Possibly. These cases are evaluated based on the specific facts of feeding history, diagnosis, and medical records, not a strict formula-only rule. An attorney can review your child's NICU records to assess whether a claim is viable. What if my child passed away from NEC? Illinois wrongful death law allows certain family members to bring a claim on behalf of a child who died from injuries caused by another party's conduct, including, potentially, a manufacturer's failure to warn. Is there a deadline to file? Yes. Deadlines vary depending on the specific facts of your case, including your child's age and the date of diagnosis. Because this is an active, evolving litigation, it's important not to wait to have your situation reviewed. Talk to an Illinois NEC formula attorney. If your premature infant developed necrotizing enterocolitis after being fed Similac or Enfamil formula, the mass tort attorneys at Phillips Law Offices can review your medical records and explain whether you may have an independent claim, separate from Abbott's recent settlement, at no cost to you. Call (312) 346-4262 or contact Phillips Law Offices online to get started.
Hope for hiv-exposed babies as Uganda receives 100 new rapid testing machines from Abbott. By Ben Musanje Global healthcare company Abbott has handed over 100 mPIMA point-of-care testing instruments to Uganda's Ministry of Health, kicking off a nationwide rollout that will see an additional 500 machines deployed to health facilities across the country. The first consignment was handed over Wednesday at the Ministry of Health's Department of National Health Laboratory and Diagnostic Services campus in Butabika, Kampala, in a move aimed at expanding access to faster HIV diagnostic services, particularly Early Infant Diagnosis (EID). Uganda currently has about 315 mPIMA instruments installed across the country. Once the new rollout is completed, the national fleet is expected to rise to approximately 815 instruments. The remaining 400 machines will be delivered in phases over the coming months in coordination with the Ministry of Health and its technical teams. The handover ceremony was attended by Minister of State for Health in charge of General Duties, Hon. Anifa Kawooya, U.S. Chargé d'Affaires Mikael Cleverley, the Director of the U.S. Centers for Disease Control and Prevention (CDC), and senior officials from the Ministry of Health, Abbott and Lifecare Diagnostics Uganda. The expansion comes as point-of-care testing continues to play a growing role in Uganda's HIV response. By the end of 2025, about half of all Early Infant Diagnosis testing in the country was being conducted at point-of-care sites. Unlike conventional laboratory systems that may require samples to be transported to central facilities before results are returned, point-of-care molecular testing brings diagnostic capacity closer to patients. This can significantly reduce delays in determining the HIV status of infants exposed to the virus, allowing health workers and caregivers to initiate treatment and care more quickly where necessary. Dr Susan Nabadda, Executive Director of Uganda National Health Laboratory Services, said point-of-care testing for viral load and Early Infant Diagnosis is helping transform the delivery of HIV services, especially in resource-limited settings. "By moving high quality molecular testing to local clinics, hospitals or delivery wards, POCT addresses the critical operational barriers of standard lab networks," Dr Nabadda said. Hassan Segujja, an Abbott representative, said the handover represented more than the delivery of equipment, describing it as part of a broader effort to bring advanced diagnostic services closer to Ugandan communities. "Today is not simply about the handover of 100 instruments, it is about a journey of a shared vision, bringing high quality molecular diagnostic testing closer to patients and communities across Uganda," Segujja said. Abbott, through its local partner Lifecare Diagnostics Uganda, will provide technical support throughout the rollout. This will include installation and commissioning of the instruments, training of health workers, preventive maintenance, corrective repairs, spare parts and technical assistance. Lifecare Diagnostics will also undertake ongoing performance monitoring to ensure the equipment is efficiently and effectively utilised. Tephy Mujurizi, Executive Director of Lifecare Diagnostics Ltd, said the company would work with the Ministry of Health to build the capacity of testers and provide sustained technical support to health facilities. "We shall provide technical support in areas of capacity building for testers, installations of these platforms at health facilities, timely services and repair as well as monitoring efficiency and effective utilization of these new innovations through continuous field mentorship and learning," Mujurizi said. The United States Government, which has supported Uganda's efforts to strengthen laboratory systems and expand access to Early Infant Diagnosis, also welcomed the partnership. U.S. Chargé d'Affaires Mikael Cleverley said the United States had supported Uganda for many years in expanding access to timely HIV diagnosis and treatment. "A stronger health system in Uganda benefits both Ugandans and Americans," Cleverley said. The partnership between Uganda, the United States, Abbott and Lifecare Diagnostics is expected to strengthen the country's decentralised diagnostic network and contribute to efforts to accelerate progress towards HIV epidemic control. The deployment also reflects the growing shift towards bringing sophisticated molecular diagnostic technologies closer to communities, reducing dependence on central laboratories and helping health workers make faster decisions about patient care. Abbott has operated in sub-Saharan Africa for nearly six decades, with its operations now spanning pharmaceuticals, nutrition, diagnostics and medical devices across the continent. Lifecare Diagnostics Ltd, Abbott's authorised distributor in Uganda, works with the Ministry of Health to support point-of-care diagnostic services, including training, equipment maintenance and field-based technical assistance across Uganda's 40 greater districts. (For comments on this story, get back to us on 0705579994 [WhatsApp line], 0779411734 & 041 4674611 or email us at [email protected]). Post Views: 455
Abbott receives FDA approval for its TactiFlex(TM) Duo Ablation Catheter to treat people with abnormal heart rhythms. Wednesday, September 09, 2026 Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex(TM) Duo Ablation Catheter, Sensor Enabled(TM) to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks. Why cardiac ablation matters for people with AFib For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke.1,2 While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart. TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, helping them tailor treatment to each patient's needs. Abbott's EnSite(TM) X EP System also provides physicians with real-time feedback as an integrated mapping solution with the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach means physicians can create precise therapeutic lesions, or small areas of scar tissue, that block the abnormal electrical signals causing an irregular heartbeat while helping minimize the impact on surrounding healthy tissue. Successfully treating these areas can help restore the heart's normal rhythm and improve outcomes for patients living with AFib. "Electrophysiology is rapidly evolving as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment," said Atul Verma, M.D., Director of Cardiology at the McGill University Health Centre in Montreal, Canada, and a globally recognized expert in pulsed field ablation technology. "TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott's EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib." Safety and effectiveness data support TactiFlex Duo FDA approval The FDA approval of TactiFlex Duo was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study recently presented at the European Society of Cardiology (ESC) Congress 2026, which was simultaneously published in EP Europace, showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go). "TactiFlex Duo represents an important advancement as Abbott builds the industry's most comprehensive electrophysiology portfolio," said Uri Yaron, senior vice president of Abbott's electrophysiology business. "From diagnosis, mapping and intracardiac ultrasound imaging to advanced treatments for the most complex arrhythmias, Abbott is uniquely positioned to support physicians at every stage of patient care. By continuing to expand our PFA portfolio and integrate innovative technologies across cardiovascular care, we're helping physicians navigate increasingly complex procedures while ensuring more patients receive the right care at the right time." Regulatory momentum across Abbott's PFA portfolio The U.S. FDA approval of TactiFlex Duo further expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. It is the company's fifth major electrophysiology approval in just over a year, following Europe's Amulet 360(TM) and TactiFlex Duo CE Mark approvals this year, and U.S. and European approvals of the Volt(TM) PFA System in 2025. Frequently Asked Questions What is TactiFlex Duo? TactiFlex Duo is an advanced cardiac ablation catheter designed to treat irregular heart rhythms. Its dual-energy feature combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single device, allowing physicians to tailor treatment to each patient's unique needs during AFib ablation procedures. How do physicians know the precise locations in the heart to treat patients with TactiFlex Duo? TactiFlex Duo is integrated with Abbott's EnSite X EP System, a sophisticated mapping system that creates highly detailed three-dimensional maps of the heart to help doctors find and treat the source of an irregular heartbeat. Working together with Abbott's Advisor(TM) HD Grid X mapping catheter, ViewFlex(TM) X ICE (intracardiac echocardiography) catheter and EnSite Echo Module, the integrated portfolio is designed to give physicians real-time images of the ablation catheter's positioning and movement, and a digital model of the patient's heart throughout a procedure. The EnSite X EP System also provides physicians with real-time information - called PFA index - which shows how the small areas of scar tissue created by TactiFlex Duo's pulsed field energy develop during an ablation procedure.3 Who may need an ablation using TactiFlex Duo? Patients with atrial fibrillation, particularly those with complex anatomy, prior or failed ablations or other challenging clinical situations, may benefit from treatment with TactiFlex Duo as determined by their physician. What are the patient benefits of being treated with TactiFlex Duo? The catheter offers physicians greater procedural flexibility and precision through dual-energy capabilities, helping treat irregular heart rhythms while reducing the potential for damage to surrounding tissue. Clinical data has shown the technology to be safe and effective. For U.S. important safety information go to: TactiFlex Duo Ablation Catheter, Sensor Enabled Volt(TM) PFA System EnSite(TM) X EP System Advisor HD Grid X Mapping Catheter, Sensor Enabled(TM) ViewFlex X ICE Catheter, Sensor Enabled(TM) and EnSite Echo Module The Amulet 360(TM) Left Atrial Appendage Occluder is approved for investigational use only in the U.S. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic 3 medicines. Its 122,000 colleagues serve people in more than 160 countries. Connect with Asianhhm Pvt Ltd at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. Source: prnewswire.com
Abbott has received US Food and Drug Administration approval for its TactiFlex Duo Ablation Catheter to treat atrial fibrillation. The device allows physicians to use pulsed field ablation, radiofrequency energy, or both during procedures, enabling tailored treatment for each patient's needs. The catheter integrates with Abbott's EnSite X EP System, which provides real-time feedback during ablation. FDA approval was based on results from Abbott's FlexPulse IDE study, presented at the European Society of Cardiology Congress 2026. This marks Abbott's fifth major electrophysiology approval in just over a year. The technology aims to help treat the 10.5 million people in the US living with atrial fibrillation, which increases stroke risk. Abbott will begin broader commercial adoption across the country in coming weeks.